HKSecWiki新股資訊 2022年06月27日
10:41 PM EDT, 06/26/2022 (MT Newswires) -- Rainmed Medical (HKG:2297) on Monday launched its initial public offering in Hong Kong, whose listing pipeline is starting to get busy again as more companies emerge from the volatility-induced market lull.
美國東部時間2022年6月26日晚上10：41(MT Newwires)--Rainmed Medical(HKG：2297)周一在香港啟動首次公開募股(IPO)，隨著更多公司走出波動引發的市場平靜，其上市流程開始再次繁忙。
The medical device maker will issue 23,348,000 shares at HK$4.28 to HK$6.24 each, a deal that could raise as much as HK$145.7 million ($18.6 million) if priced at the upper limit of the indicative range.
這傢醫療器械制造商將以每股4.28港元至6.24港元的價格發行23,348,000股股票，如果定價在指導性區間的上限，這筆交易可能籌資至多1.457億港元(合1,860萬美元)。
Of the total shares on offer, 2.33 million are earmarked for Hong Kong investors. An overallotment option of up to 3.50 million shares can be exercised if there is strong demand for the IPO.
在此次發行的全部股票中，有233萬股是為香港投資者指定的。如果IPO需求強勁，可以行使最多350萬股的超額配售選擇權。
The Suzhou-headquartered company, which counts Ping An Group (HKG:2318, SHA:601318) among its backers, expects to determine the listing price on June 30 and disclose the allocations on July 7.
這傢總部位於蘇州的公司的投資者包括平安集團(HKG：2318，SHA：601318)，預計將於6月30日確定發行價，並於7月7日披露分配情況。
Rainmed intends to start trading on the Hong Kong bourse on July 8.
Rainmed計劃於7月8日在香港交易所開始交易。
Proceeds will be used to fund the ongoing research and development, further clinical studies and preparation for the registration filing, manufacturing and commercialization of its core products.
所得資金將用於正在進行的研究和開發、進一步的臨床研究以及為其核心產品的註冊申請、制造和商業化做準備。
Huatai Financial, Zhongtai International, BOCOM International, Eddid Securities and Livermore Holdings are the joint bookrunners and lead managers of the IPO.
華泰證券金融、中泰國際、交銀國際、愛德華德證券和利華控股為此次IPO的聯席賬簿管理人和牽頭經辦人。
本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠，亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。
Was this helpful?
0 / 0
本文链接： https://hk.hksecwiki.com/news/hkp16732355/
由HKSecWiki香港券商百科整理发布，香港证券开户请访问hksecwiki.com